China has introduced market exclusivity and data protection mechanisms for the first time under the revised Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China. The revised regulation is set to take effect in May 2026.
The updated framework establishes market exclusivity of up to two years for pediatric drugs and up to seven years for orphan drugs, as long as supply commitments are met. These measures aim to give drug innovators a defined period free from direct competition. In parallel, the regulations introduce data exclusivity of up to six years for innovative chemical drugs. This new policy prevents generic manufacturers from relying on originator clinical data without authorization. This creates an additional layer of protection for intellectual property for drug originators.
While the new rules represent a major milestone, key details, such as eligibility criteria and implementation procedures, are still pending clarification from the NMPA. Overall, the reform establishes a more comprehensive, lifecycle-based innovation protection system in China.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.